Formula-based dosing for carboplatin

European Journal of Cancer

Volumn 35, Issue 9, 1999, Pages 1299-1301

  Jodrell, D I ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN;

AREA UNDER THE CURVE; BODY SURFACE; CREATININE BLOOD LEVEL; DRUG CLEARANCE; DRUG TOXICITY; EDITORIAL; HUMAN; OVARY CANCER; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0032767930     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00127-6     Document Type: Editorial

References (16)

1. J.P Sculier M Paesmans J Thiriaux A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer Eur. J. Cancer 35 1999 1314 1319
2. A.H Calvert D.R Newell L.A Gumbrell Carboplatin dosage prospective evaluation of a simple formula based on renal function J. Clin. Oncol. 7 1989 1748 1756
3. E Chatelut P Canal V Brunner Prediction of carboplatin clearance from standard morphological and biological patient characteristics J. Natl. Cancer Inst. 87 1995 573 580
4. D.I Jodrell M.J Egorin R Canetta Relationships between carboplatin exposure and tumour response and toxicity in patients with ovarian cancer J. Clin. Oncol. 10 1992 520 528
5. M.E Gore P.N Mainwaring V MacFarlane A randomised trial of high versus standard dose carboplatin in patients with advanced epithelial ovarian cancer Proc. Am. Soc. Clin. Oncol. 15 1996 A769
6. L.M Reyno M.J Egorin R.M Canetta Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer J Clin Oncol 11 1993 1156 1164
7. M.J Egorin D.A Van Echo E.A Olman Prospective validation of a pharmacologically based dosing scheme for the cis -diamminedichloroplatinum (II) analogue diamminecyclobutanedicarboxylatoplatinum Cancer Res. 45 1985 6502 6506
8. A.H Calvert A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel Semin. in Oncology 24 Suppl. 2 1997 85 90
9. O Shemesh H Golbertz J.P Kriss Limitations of creatinine as a filtration marker in glomerulopathic patients Kidney Int. 28 1985 830 858
10. A.S Levy R.D Perrone N.E Madias Serum creatinine and renal function Ann Rev Med 39 1985 465 490
11. M.J Millward L.K Webster G.C Toner Carboplatin dosing based on measurement of renal function—experience at the Peter MacCallum Cancer Institute Australian and New Zealand J. of Med. 26 1996 372 379
12. M.J Egorin D.A Van Echo S.J Tipping Pharmacokinetics and dosage reduction of cis -diammine(1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function Cancer Res. 44 1984 5432 5438
13. R.W Jeliffe Creatinine clearance bedside estimate Ann. Intern. Med. 79 1973 604
14. D.W Cockcroft M.H Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
15. G Daugaard N Rossing M Rorth Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high dose Cancer Chemother. Pharmacol. 21 1988 163 167
16. J.G Wright A.H Calvert M.S Highley Accurate prediction of renal function for carboplatin dosing Proc. Am. Assoc. Cancer Res. 40 1999 384